Previously, Dr. Alexander held executive positions at big-name companies including Takeda Pharmaceuticals, Pfizer, AstraZeneca and Merck.
He is certified by the American Board of Psychiatry and Neurology and specializes in psychopharmacology.
“Robert’s extensive experience as a biotech industry veteran will be crucial as we continue to progress RE104 through the clinic and approach our phase 2 study launch in postpartum depression,” Greg Mayes, Reunion’s president and CEO, said in a Jan. 18 press release. “Following Reunion’s successful interim data analysis for its Phase 1 trial with lead asset RE104, Robert will further guide us in advancing RE104 to the next stage of development for the millions of patients in need.”
